Gal-3 has also been discovered to have an intricate prognostic role, which changes according on the type of tumor: higher Gal-3 expression has been linked to a worse prognosis in numerous malignancies, including lymphoma, thyroid cancer, and leukemia, whereas lower Gal-3 expression has been linked to a worse outcome in prostate cancer and chronic lymphoblastic leukemia (106). This evidence concerns the gene LGALS3 and prostate cancer.